Bristol-Myers Squibb (NYSE:BMY) shares sold by Orion Portfolio Solutions LLC

Orion Portfolio Solutions LLC lessened its holdings in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 6.9% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 43,360 shares of the biopharmaceutical company’s stock after selling 3,205 shares during the quarter. Orion Portfolio Solutions LLC’s holdings in Bristol-Myers Squibb were worth $2,351,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Northwest Financial Advisors purchased a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at about $27,000. Accordant Advisory Group Inc acquired a new stake in Bristol-Myers Squibb in the 1st quarter valued at approximately $31,000. Pacific Capital Wealth Advisors Inc. acquired a new stake in Bristol-Myers Squibb in the 4th quarter valued at approximately $34,000. Turtle Creek Wealth Advisors LLC purchased a new stake in Bristol-Myers Squibb in the 4th quarter valued at approximately $40,000. Finally, Wetzel Investment Advisors Inc. purchased a new stake in Bristol-Myers Squibb in the 4th quarter valued at approximately $40,000. 76.41% of the shares are currently owned by institutional investors and hedge funds.

Bristol-Myers Squibb trading rose 0.6%

Shares of Bristol-Myers Squibb stock opened at $42.64 on Friday. The company has a fifty day simple moving average of $41.68 and a 200 day simple moving average of $47.02. The company has a quick ratio of 0.99, a current ratio of 1.11, and a debt-to-equity ratio of 2.99. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $65.38.

Bristol-Myers Squibb (NYSE:BMY – Get Your Free Report ) last issued its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, topping the consensus estimate of ($4.53) by $0.13. The business had revenue of $11.87 billion during the quarter, compared to analysts’ expectations of $11.45 billion. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. Bristol-Myers Squibb’s revenue was up 4.7% compared to the same quarter last year. In the same quarter last year, the company posted earnings of $2.05 per share. equities analysts predict that Bristol-Myers Squibb will post 0.55 earnings per share for the current fiscal year.

Bristol-Myers Squibb announces dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, August 1st. Investors of record on Friday, July 5th will be issued a dividend of $0.60 per share. The ex-dividend date of this dividend is Friday, July 5. This represents an annualized dividend of $2.40 and a dividend yield of 5.63%. Bristol-Myers Squibb’s dividend payout ratio is -77.42%.

The Wall Street analyst weighs in

BMY has been the subject of several analyst reports. William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. Wells Fargo & Company upped their target price on Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research report on Thursday, April 18th. BMO Capital Markets dropped their target price on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a research report on Friday, April 26th. Barclays cut their price target on Bristol-Myers Squibb from $43.00 to $41.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 10th. Finally, StockNews.com lowered Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Thursday, June 27th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $59.07, according to MarketBeat.

Read our latest research report on BMY

Bristol-Myers Squibb Company Profile

(Free report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic and neuroscience. The company’s products include Eliquis for reducing the risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anticancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Further reading

Want to see what other hedge funds BMY owns? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY – Free Report).

Get news and reviews for Bristol-Myers Squibb Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bristol-Myers Squibb and related companies with MarketBeat.com’s FREE daily email newsletter.